US 12,280,142 B2
Compositions for preventing infection
Thomas Meyer, Zuchwil (CH); and Fabio Fais, Kembs (FR)
Assigned to Altamira Medica AG, Zug (CH)
Filed by Altamira Medica AG, Zug (CH)
Filed on Sep. 3, 2021, as Appl. No. 17/466,142.
Claims priority of provisional application 63/230,191, filed on Aug. 6, 2021.
Claims priority of provisional application 63/173,816, filed on Apr. 12, 2021.
Claims priority of provisional application 63/119,237, filed on Nov. 30, 2020.
Claims priority of provisional application 63/075,590, filed on Sep. 8, 2020.
Prior Publication US 2022/0071893 A1, Mar. 10, 2022
Int. Cl. A61K 9/00 (2006.01); A61K 33/00 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/36 (2006.01); A61P 31/16 (2006.01)
CPC A61K 9/006 (2013.01) [A61K 33/00 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/36 (2013.01); A61P 31/16 (2018.01)] 24 Claims
 
1. A sprayable aqueous intranasal composition comprising:
about 0.1% to about 0.8% by weight of a mucoadhesive polymer;
about 1.7% to about 2.8% by weight of a clay;
about 30% to about 40% by weight of caprylic/capric triglyceride; and
one or more chelating agents;
wherein the composition has no more than 0.5% by weight of preservatives; and
wherein the composition is thixotropic.